Ten63 Therapeutics

About Ten63 Therapeutics

TEN63 is a company focused on revolutionizing drug discovery through advanced technologies like AI and quantum simulations. Their mission is to tackle the toughest challenges in drug discovery, create groundbreaking therapeutics, and ensure no patient is out of options by pursuing high-impact, previously undruggable targets.

Products & Services

BEYOND Platform:A platform that uses AI and quantum simulations to accelerate drug discovery and enable the pursuit of critical, data-poor targets with generative chemistry.

Pipeline:A collection of groundbreaking therapeutics under development, targeting high-impact areas in drug discovery.

Specialties

AI in Drug Discovery Quantum Simulations Generative Chemistry Targeting Undruggable Targets

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 15900000 MR: - FA: 15.9 million FAN: 15900000	D: 2023-05-02 FD: 2023-05-02	7 investors

Series A Latest

2023-05-02

$15.9M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Marcel Frenkel

Co-Founder and CEO

M

Mark Hallen

Co-Founder and CTO

A

Andrew Graham

CFO

C

Charlie Holst

VP and Head of Biology

N

Nathan Guerin

Director of Engineering

N

Nancy Miller-Rich

Co-Founder

View 16 more team members with Pro

Unlock Full Team Directory

Recent News